Anupam RasayanQ1 FY27
Anupam Rasayan Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹1,265P/E: 81.0Market Cap: ₹14.2K CrSector: Chemicals & Petrochemicals
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
Yes
Order
Yes
Capex
No
2 of 5 growth signals are positive.
Full analysisRevenue guidance
Category 2- →Organic revenue growth expected at around 25% ± a couple of percentage points annually.
- →Addition of Jayhawk's revenue contributes an incremental 10% to 15% growth, as Jayhawk was not included in previous years.
- →Overall growth from existing three companies (Anupam, Tanfac, Jayhawk) anticipated to be strong, with Jayhawk contributing approx. INR140-150 crores this quarter.
- →Growth excluding Jayhawk was single-digit, reflecting a seasonal tepid Q1.
- →Post-consummation of Bliss GVS Pharma acquisition, further growth expected by improving asset utilization from current ~30% to 60-70% over 2-3 years.
- →Bliss integration will likely stimulate growth via combined sales and marketing efforts.
- →Long term opportunities exist with new product pipelines and LOIs such as BASQUEVOLT (~USD300 million over 10 years).
- →Stable growth expected across Agri, Pharma, and Performance Materials segments with shifting portfolio mix.
Margin guidance
Category 3- →Organic revenue growth expected around 25% (+/- a few percentage points) for FY27 from existing companies (Anupam, Tanfac), plus an additional 10-15% growth from Jayhawk's inclusion.
- →Bliss acquisition anticipated to improve utilization from ~30% to 60-70% over 2-3 years, supporting future revenue and margin expansion.
- →EBITDA margins expected to stabilize in the range of 22-24% consolidated and 24-26% standalone over the next 2-3 years.
- →PAT growth was 6% YoY in Q1 FY27 despite 35% EBITDA growth, due partly to increased depreciation and interest from the expanded asset base.
- →Future profit growth to improve as new product commercialization scales and operational efficiencies increase.
- →Capex largely completed; focus on selective investments based on customer visibility and returns, limiting margin pressure.
- →Working capital efficiency expected to improve, supporting cash flow and profitability expansion over time.
3 more insights locked — sign up free to unlock
Fundraise plans
Yes- →For the Bliss acquisition, a debt of around INR 300 crores is planned through a fully owned subsidiary of Anupam to acquire the stake from selling shareholders.
- →Bliss itself has healthy cash flow (~INR 200+ crores) and no debt, so they do not foresee a large external capital requirement for any API asset acquisition; internal accruals are expected to be sufficient.
- →Any further funding needed by Bliss may come from leveraging their robust balance sheet or internal working capital like receivables.
- →Apart from this, Anupam does not currently see a major capex or capital raising requirement; the major capex cycle is complete with only selective incremental spend planned (~INR 70-80 crores).
- →Interest costs are expected to remain at current run rates without significant increases.
- →Anupam continues to explore acquisition opportunities, but no specific new fundraising for those is indicated at this stage.
Order book
Yes- →The order book revenue for the last year was roughly around INR 400 crores.
- →This revenue is expected to be significantly higher this year, contributing around 25% of total revenue.
- →Going forward, the order book is anticipated to contribute around 30% of total revenue.
- →Most products in the order book have been or are expected to be commercialized by this year or the next year.
- →Overall, there is a strong ramp-up occurring in the order book execution and conversion to revenue.
Capex plans
No- →Major capex cycle for existing Anupam platform has been completed, with all major projects commissioned and operational. (Page 6)
- →Future capex expected to be limited, primarily for repair, maintenance, repurposing, or new product introductions. (Page 9)
- →Guided capex range for FY27 is approximately INR 70-80 crores, focused mainly on standalone business. (Page 9)
- →Jayhawk is well capitalized, unlevered, and expected to fund its own capex for growth, repurposing, or replacements without Anupam's funding support, at least in near term. (Page 9)
- →Strategic investments include the ongoing Bliss GVS Pharma acquisition (expected to close by H1 September), which will expand pharmaceutical capabilities. (Pages 6-16)
- →Letter of Intent with BASQUEVOLT involves potential long-term revenue of ~USD 300 million over 10 years, with commercialization expected from FY27. (Page 5)
How does Anupam Rasayan rank vs peers in Chemicals & Petrochemicals?
Pro feature1Anupam Rasayan
Rev 2Mar 3
See full Chemicals & Petrochemicals sector rankings
How does Anupam Rasayan rank in Chemicals & Petrochemicals?
Compare Anupam Rasayan against every Chemicals & Petrochemicals company (Q1 FY27) on revenue, margins and earnings-call signals.